Podcasts about Parkinson

We are all building a case for something every single day. The question is whether you are building a case for what you are capable of, or a case for why you cannot. In this episode I name the ways we argue for our own limitations, often with impressive precision. We have evidence. We have history. We have a courtroom's worth of justification for why change is not available to us. I also speak to the label trap, the way certain words or diagnoses can become the closing argument in a case for brokenness rather than the door that opens inquiry. I have coached women navigating cancer, Parkinson's, and ALS, and I would not have been doing that work if I believed a diagnosis was the final word on what someone was capable of. You can argue for your possibility or your limitations. You cannot do both at the same time. This episode challenges you to choose which case is worth building. Ready to go deeper? Grab my book, The Consistency Code: A Midlife Woman's Guide to Deep Health and Happiness, at https://theconsistencycode.com    #GraceAndGrit #Mindset #MidlifeWomen #SelfLeadership #Possibility #WomensWellness #DeepHealth #OvercomingLimitations #GrowthMindset #IntentionalLiving

Why work expands to fill the time available, and how small business owners can use deadlines, time blocking, and clear outcomes to get more done in less time. Show Notes Page: https://www.thehowofbusiness.com/616-parkinsons-law-for-small-business/ Have you ever noticed that a task you expected to finish in a day somehow ends up taking all week? Parkinson's Law explains why and understanding it can help small business owners reclaim their most limited resource: their time. Parkinson's Law is the principle that work expands so as to fill the time available for its completion. Give yourself an entire day to complete an administrative task and it will often consume the entire day. Give your team two weeks to finish a project and much of the meaningful work tends to happen in the final two days. For small business owners, this helps explain why we feel constantly busy, why meetings and projects drag on, and why there never seems to be enough time for the high-value work that actually grows the business. In this episode of The How of Business, Henry Lopez explores how understanding Parkinson's Law can help you and your team make faster progress and use your limited time more effectively without simply working longer hours. The concept was introduced by British historian and author C. Northcote Parkinson in a 1955 essay in The Economist. His observation was simple: when more time is available, work tends to become more complicated and consume all the time available. It's a bit like a bigger house that we fill with more stuff. The more time we have, the more we tend to fill it. Give yourself an hour to write an email and you may spend the full hour refining it; give yourself fifteen minutes and you'll likely communicate the same message just as well. Henry, a self-described perfectionist, is candid about how this applies to his own work, where the pursuit of perfection often produces diminishing returns. The first 80% of a result might take two hours, while chasing perfection can consume six more without making it materially more valuable to the customer. When work continually expands, the consequences add up: higher labor costs, slower execution, delayed revenue, missed opportunities, decision fatigue, too much owner involvement, and less time for planning and growth. Henry also raises a hard question worth sitting with: does your business culture reward activity instead of results? The heart of the episode is a set of eight practical tactics for putting reasonable constraints around your work, plus five questions you can ask to right-size any recurring task or project. As Henry puts it, "Don't just ask how much time do we have. Instead, ask how much time should this result require?" This episode is hosted by Henry Lopez. The How of Business podcast focuses on helping you start, run, grow and exit your small business. The How of Business is a top-rated podcast for small business owners and entrepreneurs. Find the best podcast, small business coaching, resources and trusted service partners for small business owners and entrepreneurs at our website https://TheHowOfBusiness.com

Eric begins with major show news before pivoting to the jackassery of the week with Eliot. They then analyze Trump's interactions with Bibi Netanyahu and Vladimir Zelensky at Lindsey Graham's funeral and discuss the ways in which the Iranian and Ukrainian wars are increasingly intertwined. The two discuss Iran's ongoing unwillingness to "take yes for an answer" as evidenced by their recent strikes across the region. Historian and Professor Robert Parkinson then joins the show to discuss his recent book Tyrants and Rogues: Understanding the Declaration of Independence. Parkinson explains his focus on the twenty-seven colonial grievances listed in the Declaration, the crown's misjudgments in attempting to address colonial discontent, and Thomas Jefferson's additional two grievances that were edited out--among other topics.Greg Jaffe & Kate Kelly in the New York Times on Adm. Daryl Caudle:https://www.nytimes.com/2026/07/26/us/politics/caudle-navy-hegseth-parlatore-promotion.htmlTyrants and Rogues: Understanding the Declaration of Independencehttps://a.co/d/0bPfR7hlShield of the Republic is a Bulwark podcast co-sponsored by the Miller Center of Public Affairs at the University of Virginia.

Joining Kiri Pritchard-McLean this week is comedian Michelle Wolf who reflects on home births, Professor Stephen Wallace explains how old plastic bottles can be transformed into a form of Dopamine that can be used to treat Parkinson's disease, and Dr Matt Clarke demonstrates the power of medical collaboration in helping to identify and treat brain tumours.Best Medicine is your weekly dose of laughter, hope and incredible medicine. Award-winning comedian Kiri Pritchard-McLean is joined by a funny and fascinating panel of comedians, doctors, scientists, experts and historians to celebrate medicine's inspiring past, present and future.Each week Kiri challenges a panel of experts and a comedian to make a case for what they think is 'the best medicine'. Each guest champions anything from world-changing science or an obscure invention to an everyday treatment, an uplifting worldview, an unsung hero or a futuristic cure.Whether it's groundbreaking surgery, seaweed underwear, AI glasses to help people with dementia, horse therapy, sports, revolutionary gene therapy for Huntington's disease or yesterday's rubbish becoming tomorrow's medicines - it's always something worth celebrating.Hosted by Kiri Pritchard-McLeanFeaturing: Dr Matt Clarke, Professor Stephen Wallace and Michelle WolfWritten by Edward Easton, Jordan Gray, Kiri Pritchard-McLean and Ben RowseProducer: Tashi RadhaExecutive Producer: Ben WorsfieldTheme tune composed by Andrew JonesA Large Time production for BBC Radio 4

Leading brain health and neurological organisations are warning the country is training specialists only to lose them, due to a lack of funded hospital positions. The Neurological Alliance, is calling on the Government to fund two additional public hospital neurology positions every year and commit to developing a national neurological workforce strategy to plan for the future. The Alliance represents 20 New Zealand organisations including Stroke, Dementia, Parkinson's, and Epilepsy New Zealand, who advocate collectively for the interests of the estimated 1.5 million New Zealanders living with neurological conditions. Chair of Neurological Alliance, Rich Easton, says the shortage of neurologists is already significant consequences across the health system including long wait times and declined referrals. Chair of Neurological Association - which represents neurologists - Dr. James Cleland says the ageing workforce is not being replaced fast enough, and more training places are desperately needed.

In this episode, we dive into a major scientific review published in Nutrients regarding the unique metabolic pathways of Medium-Chain Triglycerides (MCTs).While most dietary fats follow a complex digestive route, new data from MDPI Nutrients reveals that MCTs—specifically C8 and C10—exhibit a distinct biological advantage. By bypassing the traditional lymphatic system and moving directly to the liver via the portal vein, these functional lipids are prioritized for oxidation. This process not only supports thermogenesis but also efficiently generates ketone bodies, providing a reliable, insulin-independent fuel source for the brain.We explore the clinical evidence across four critical domains:• Metabolic Precision: How MCTs influence energy expenditure, appetite regulation, and the synchronization of lipolysis to support healthy weight management.• Neuroprotection: The role of ketogenic energy in supporting mitochondrial health and offering an alternative fuel for those managing Alzheimer's or Parkinson's.• Intestinal Integrity: The impact of MCT metabolites on the gut microbiome and the repair of the intestinal barrier.• Muscular Longevity: Emerging research on enhancing mitochondrial biogenesis and protecting against muscle wasting (sarcopenia) in aging populations.Formal Citation: Yu Y, Ya W, Zhang J, Wang J, Sun B. Recent Advances in Medium-Chain Triglycerides in Chronic Disease Prevention. Nutrients. 2026; 18(13):2133. https://doi.org/10.3390/nu18132133#Science #Metabolism #Ketosis #BrainFuel #Nutrients #MDPI #CatalystAnalysis #MCT #STEM #Neuroprotection #Sarcopenia #VHFILM________________________________________

Herzlich Willkommen bei meinem Podcast "Jetzt erst recht – Positiv leben mit Parkinson". Mein heutiger Gast ist Kathrin Feile. Kathrin ist unter anderem Lehrerin, Künstlerin und Autorin und diese vielfältigen Talente sorgen dafür, dass sie die Dinge kritisch hinterfragt und viele kreative Ideen hat. So hatten wir ein wunderbares Gespräch über Eigenverantwortung, Empowerment, über Kathrins hilfreiche Erfahrungen mit Ayurveda und über ihr Buch, das vor kurzem veröffentlicht wurde. Ich wünsche dir viel Freude beim Hören! Links zu dieser Folge: Kontakt zu Kathrin: Kathrin.Feile@gmx.de Link zu Kathrins Buch "Kaninchens Traum. Ein neurologischer Abenteurroman": https://buchshop.bod.de/kaninchens-traum-kathrin-feile-9783696397364 Ich freue mich über deine Rückmeldung zu dieser Podcastfolge. Schreib mir gerne: kontakt@jetzt-erst-recht.info

>p>Broadcast from KSQD, Santa Cruz on 7-30-2026: A type of coffee brewed from beans that have been altered by passage through the digestive track of civet cats is a delicacy in Southeast Asia. A Scientific Reports paper using gas chromatography analyzed Kopi Luwak (civet-processed coffee beans) versus fresh-picked beans, finding elevated caprylic and capric acids that carry the characteristic flavor notes found in dairy products. Dr. Manuel Esteller sampled and tested the blood, saliva, urine, and stool of the oldest human Maria Branyas Morera, who died last year at 117. Despite exceptionally short telomeres, she carried anti-inflammatory genetic variants seen in long-lived dogs, worms, and flies, and had unusually high Bifidobacterium levels—likely boosted by her three-daily-servings-of-yogurt habit. Dr. Dawn defends sunscreen use against Environmental Working Group scare campaigns, noting that concerns about absorption of sunscreen ingredients into blood remain theoretical while sunburn's melanoma link is well-established. She argues that a badly sunburned toddler starts a clock that can produce melanoma by the late teens. The FDA advisory committee is reviewing certain short amino acid chains popularly known as "peptides" for potential compounding-pharmacy production, covering proposed to treat ulcerative colitis, wound healing, insomnia, insulin resistance, migraines, and osteoporosis. Dr. Dawn flags that five to seven committee members have industry conflicts of interest, but argues that even flawed approval is preferable to the current gray market, where analysis shows vials contain only 4-28% of labeled content along with endotoxin and toluene contamination. She proposes surveillance tracking of prescribed peptides to catch adverse effects early, citing a foreign melanocortin nasal spray tanning product that caused rare nasal melanomas as a cautionary example. Utah State biochemists working with the Cas12a2 CRISPR enzyme discovered that instead of behaving as a precise gene-editor like Cas9, it goes into an indiscriminate DNA-shredding mode after recognizing its target RNA. By programming it to recognize RNA sequences uniquely activated in cancer cells (embryonic-development genes that shouldn't be running in adults), researchers destroyed only the cancer cells in tissue culture, potentially offering a way to eliminate small metastases without healthy tissue toxicity. Cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitor therapy showed dramatically improved outcomes, with median survival in advanced lung cancer rising from 20 to 37 months. Non-mRNA vaccines (flu, pneumonia) showed no such benefit. Lab work suggests the mRNA triggers type-1 interferon release that activates tumor-infiltrating immune cells and drives them to lymph nodes to train other immune cells against the tumor. Researchers redesigned a CD40 agonist antibody to bind multiple receptors simultaneously by clustering with a second antibody, stretching the cell surface and triggering a powerful immune response. In a 12-patient trial, injecting one tumor caused all tumors to shrink in six patients and produced complete remission in two—including a melanoma patient with dozens of leg tumors and a metastatic breast cancer patient whose lung and liver tumors resolved after skin injection. Two small trials of CAR natural killer cells—engineered like CAR T-cells but derived from donor umbilical cord blood and thus potentially available off-the-shelf—showed remarkable results in autoimmune disease. All 27 systemic lupus patients targeting the CD19 protein on autoantibody-producing cells showed improvement, with some remaining in remission at nearly two years. A single Shanghai patient with systemic sclerosis showed restoration of normal skin and blood vessel structure. A paradox has emerged in advanced prostate cancer: while blocking testosterone halts early tumor growth, cancer cells eventually adapt to low-androgen conditions such that flooding tissues with testosterone in advanced disease can actually halt tumor progression by triggering cellular redifferentiation. Separately, Dr. Dawn reviews conflicting evidence on Parkinson's risk from androgen deprivation therapy, singling out enzalutamide (Xtandi) as the most concerning drug due to blood-brain barrier penetration, and recommending darolutamide as the safest alternative with matching prostate efficacy but minimal CNS entry.

This month we're interviewing a handful of fascinating people as part of our summer ‘Parky Profiles' series.It's hard to ignore the activities of The Michael J. Fox Foundation. Since its founding in 2000, it has raised over $3 billion in the hunt for a Parkinson's cure. It's the largest non-profit funder of research in to the disease.We've all heard of its founder and namesake, but who is the head honcho making the everyday decisions? We managed to pin down the incredibly busy Deborah Brooks, CEO and co-founder of the foundation. We chat to her about her journey from the world of finance to non-profit and what her dreams are for the MJFF. Movers & Shakers is brought to you in partnership with Cure Parkinson's.Presented by Rory Cellan-Jones, Gillian Lacey-Solymar, Mark Mardell, Paul Mayhew-Archer and Sir Nicholas MostynProduced and edited by Ewan Cameron for PodotAssociate Producer: Lulu GoadMusic by Alex StobbsHosted on Acast. See acast.com/privacy for more information. Hosted on Acast. See acast.com/privacy for more information.

Viagra's Cancer Signal, TV's Toll on Your Brain, Heat and Accelerated Aging, and a New Way to Flush Your Brain Explained Viagra's Active Ingredient May Block Cancer From Spreading A study published in Cancer Research from the Weizmann Institute of Science, in collaboration with Clalit and the U.S. National Cancer Institute, found that sildenafil, the active ingredient in Viagra, may interfere with cancer cells' ability to metastasize by disrupting how they regulate cholesterol, a resource tumors need to detach and invade new tissue. The team combined mouse models and human cell cultures with more than twenty years of medical records covering roughly five million people, and found better survival outcomes among about forty thousand cancer patients who had taken sildenafil before diagnosis. Researchers also flagged a possible combination effect with statins. Host Dave Asprey breaks down why this cheap, off-patent drug class deserves more attention than it's getting, and where it fits alongside his own longevity protocol. Source: https://www.healthline.com/health-news/viagra-may-stop-cancer-from-spreading-study ~~ Heavy TV Watching In Midlife Tied To Alzheimer's-Related Brain Changes A nearly twenty-four-year study published in Alzheimer's & Dementia followed more than 1,700 adults, tracking TV habits in their early fifties and scanning their brains in their mid-seventies. Men who watched more TV showed greater white matter damage and smaller frontal and occipital lobes, while women showed no such association. Critically, people with desk jobs that kept them sedentary all day did not show the same brain changes, and the TV association held even after adjusting for exercise levels. Host Dave Asprey unpacks why passive screen time, not sitting itself, may be the real driver here. Sources: https://www.the-independent.com/life-style/tv-time-linked-alzheimers-study-b3023054.html https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71582 ~~ Ambient Heat Exposure Linked To Faster Biological Aging A Science Advances study of 3,686 older adults linked neighborhood-level heat index exposure to accelerated biological aging using DNA methylation clocks. Short-term heat exposure moved one clock significantly, while exposure sustained over a full year or six years moved all major clocks, with extreme-caution heat days tied to nearly a three-year jump in one aging measure and a five percent faster overall aging pace on another. Researchers point to inflammation and stress signaling as likely drivers. Host Dave Asprey explains why this is a fundamentally different kind of heat story than the sauna and cold-plunge conversation biohackers are used to. Source: https://www.science.org/doi/10.1126/sciadv.adr0616 ~~ Industrial Chicken Farming May Be Accelerating The Spread Of Drug-Resistant Bacteria A genomic analysis of nearly 2,800 bacterial samples from chickens and wild birds across thirty countries, published in PNAS and covered by The Guardian, found a roughly hundredfold increase in Campylobacter strain transitions between wild birds and farmed chickens since 1900. Global chicken populations have grown sevenfold since the 1960s to about 27 billion birds, and researchers identified genetic adaptations tied to antimicrobial resistance developing inside that population. Sixty to eighty percent of human Campylobacter infections trace back to raw chicken, with links to post-infectious IBS in some cases. Host Dave Asprey connects the dots between industrial farming density and the gut-health stakes for anyone who eats chicken. Sources: https://www.theguardian.com/food/2026/jul/27/industrial-chicken-farming-accelerating-spread-of-diarrhoea-bacteria-study-finds https://doi.org/10.1073/pnas.2609969123 ~~ VA Researchers Develop Breathing-Based "Brain Flush" For Parkinson's And Alzheimer's VA researchers led by Dr. Henry Lin found a way to trigger the brain's glymphatic clearance system, normally active during deep sleep, in people who are awake, using alternating puffs of five percent carbon dioxide and room air every thirty-five seconds. In a study of thirty Parkinson's patients and thirty-three healthy controls, a single thirty-minute session produced measurable increases in blood levels of beta-amyloid, alpha-synuclein, and other waste proteins associated with neurodegeneration. The VA's Technology Transfer Program is now developing a patent and prototype device. Host Dave Asprey explains why this gives breathwork protocols a real physiological mechanism instead of just a hunch. Source: https://www.research.va.gov/currents/0426-Exciting-new-treatment-being-developed-for-Parkinsons-Alzheimers.cfm ~~~ This episode is designed for biohackers, longevity enthusiasts, and high-performance listeners who want mechanism-level insights into an overlooked cancer drug repurposing story, the real difference between passive and active screen time, a new angle on heat as a biological stressor, the hidden gut-health cost of industrial poultry farming, and a breathing technique that may unlock your brain's own detox system. Host Dave Asprey connects clinical research, large-scale genomic data, and translational neuroscience into practical frameworks for improving longevity, gut health, and brain performance. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: sildenafil cancer metastasis, Viagra cancer research, cholesterol cancer cells, PDE5 inhibitor longevity, TV Alzheimer's risk, screen time dementia, white matter brain aging, passive sedentary behavior brain, ambient heat epigenetic aging, DNA methylation clock, heat index biological aging, industrial chicken farming bacteria, Campylobacter antibiotic resistance, foodborne illness IBS, glymphatic system brain flush, CO2 breathing brain detox, Parkinson's Alzheimer's treatment, VA brain research, biohacking news 2026, Dave Asprey, The Human Upgrade Thank you to our sponsors! - Suppgrade Labs | Get real restorative sleep with Quiet Mode. Use code DAVE15 at shopsuppgradelabs.com. - Timeline | Visit timeline.com/dave to learn more about Mitopure and get 20% off your first order for a limited time. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:19 – Story #1: Viagra & Cancer 02:01 – Story #2: TV Watching & Brain Aging 03:16 – Story #3: Heat Exposure & Biological Age 04:46 – Story #4: Chicken Farming 06:34 – Story #5: CO2 Therapy & Brain Detox See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week we're joined by sisters in life and in business, Jenny Bloom and and Courtney Malkin to celebrate their stylish, selfless and always entertaining mom, Momma Robin. Jenny and Courtney share how their mom was a reluctant home cook, but a fabulous baker and still to this day the ultimate queen of "Snicky snacks". We learn about all of Momma Robin's favorite things including white wine over ice, candy from her bedside table, Paris vacations, competitive Mahjong, and making sure her daughters are wearing enough blush. She has also been known to sake bomb and beer bong, give away the clothes off her back, and experiment with Ozempic after a few drinks. Underneath all the laughs is a woman who took care of everyone, including her husband throughout his long battle with Parkinson's, her aging parents, her daughters and her beloved grandchildren. The Bloom Sisters say it best 'Momma Robin, you are the pillar of the family and we're so lucky to have you'! All Things Courtney & Jenny Website - https://www.bloomerangpr.com/ Linkedin - https://www.linkedin.com/company/bloomerang-pr/ Bloomerang on Instagram - https://www.instagram.com/bloomerangpr Jenny on Instagram - https://www.instagram.com/thejennybloom/ Courtney on Instagram - https://www.instagram.com/courtmalk/ About Hey Sis, Eat This Hey Sis, Eat This is hosted by Courtney Ashley & Whitney Wolder Follow us on social media @heysiseatthis Visit our Website for recipes and more heysiseatthis.com Contact us at hello@heysiseatthis.com

In this episode of Dean's Chat, Drs. Jeffrey Jensen and Johanna Richey welcome Dr. Karen Langone, a longtime leader in podiatric medicine, past president of the American Association for Women Podiatrists, former leader/past president within the American Association of Podiatric Sports Medicine, and active advocate through the New York State Podiatric Medical Association and APMA. Karen shares her journey into professional leadership, explaining how mentors and role models encouraged her to become involved and how years of volunteering ultimately led to opportunities to influence the profession at the state and national levels. She emphasizes the importance of giving back and recognizing that meaningful leadership often begins by simply raising your hand and doing the work.A passionate biomechanics and sports medicine specialist, Karen discusses her fascination with human movement and how that interest has evolved throughout her career. She reflects on the evolution of biomechanics from traditional approaches toward tissue stress theory and emphasizes the value of continually learning from colleagues and sharing the small clinical pearls that can improve patient care. Her clinical interests have expanded beyond sports medicine to include falls prevention, osteopenia, osteoporosis, and helping patients with neurologic conditions such as Parkinson's disease maintain mobility and independence. She highlights the profound role podiatrists can play in preventing falls and preserving function throughout a patient's lifetime.Karen also reflects on her involvement in the development of the Special Olympics Fit Feet program, describing the opportunity to provide biomechanical assessment, gait analysis, and foot care to athletes while helping establish a foundation for a program that continues to benefit patients today. The discussion explores the importance of serving vulnerable populations and the responsibility healthcare professionals have to address unmet needs.The conversation also examines the evolution of women in podiatric leadership. Karen shares her experiences as one of the early women involved in leadership within sports medicine and discusses how mentorship, representation, and strong female role models have helped create greater opportunities for women throughout the profession. She emphasizes that leadership is not about competing with others—excellence is not a zero-sum game—and that professionals can disagree respectfully, learn from different perspectives, and ultimately work together for the greater good.Finally, Karen discusses the changing landscape of podiatric practice and the evolving educational needs of today's DPMs including some highlights of the upcoming National Conference in Nashville Tennessee, including sessions on leadership, employment models, contracts, RVUs, hospital opportunities, and work-life alignment. Her message to students considering podiatry is simple and powerful: podiatrists have the opportunity to build meaningful, long-term relationships with patients while helping them maintain the mobility that allows them to live their lives. This episode is a compelling conversation about leadership, service, biomechanics, mentorship, advocacy, and the many ways podiatrists can make a lasting difference.

LetsTalkAboutItChris Johnson revealed that he has ALS. The former Titans star publicly announced the diagnosis June 29 and said doctors believe he has sporadic ALS. Tennessee has since supported Johnson's effort to revive the Ice Bucket Challenge and will honor him in its Ring of Honor. This is bigger than football and has to lead the show.Ahman Green revealed an early-onset Parkinson's diagnosis. The Packers' all-time leading rusher said he was diagnosed in January 2025 after initially noticing symptoms during sleep. Green said he remains optimistic and is managing the condition through medication, exercise and diet.Deebo Samuel is returning to the 49ers. San Francisco reunited with its former playmaker on a one-year deal worth up to $7 million as the organization deals with uncertainty throughout its receiver room.Tampa Bay's contract situation is becoming a full organizational problem. Baker Mayfield says he feels undervalued after extension talks stalled, while Vita Vea has requested a trade and is drawing substantial interest. Two of the team's most important leaders entering camp are publicly unhappy.The Eagles reset the defensive tackle market for Jalen Carter. Philadelphia reportedly gave Carter a four-year, $152 million extension, making him the highest-paid defensive tackle in the league.Aaron Donald comeback speculation is real enough to discuss. Donald has resumed on-field work, Sean McVay has not exactly shut down the conversation and Myles Garrett has openly entertained what the pairing could accomplish for the Rams.Brandon Aiyuk and the 49ers remain headed toward an ugly ending. Aiyuk has publicly aired grievances, repeatedly connected himself to Washington and reportedly allowed communication with the Commanders to fall “off the track.”Aaron Rodgers says 2026 is his final season. Rodgers returned to play for Mike McCarthy in Pittsburgh but says there is “zero debate” about another season in 2027.CollegeFootballNewsThe 2027 quarterback evaluation cycle is underway. Oregon's Dante Moore is already receiving comparisons to C.J. Stroud, while Darian Mensah has reportedly generated legitimate franchise-quarterback evaluations from scouts.Brendan Sorsby has made the supplemental draft relevant again. Dallas reportedly viewed the former Texas Tech quarterback as a developmental option, and his availability has created a real discussion about whether teams should spend future draft capital this summer.The next running-back class is beginning to form. Early rankings and breakout lists are already moving the conversation away from the completed 2026 draft and toward which college runners can emerge during the upcoming season.Rookie evaluations are finally moving from draft grades to football. Fernando Mendoza has signed his deal with the Raiders, Ty Simpson is under contract with the Rams and players such as Caleb Downs and Jeremiyah Love are entering camp with immediate expectations.TakeOrTangentThe football cost may be showing up years after retirement. Johnson and Green played the same position during an era that celebrated running backs absorbing extreme physical punishment. Their diagnoses can lead into a deep discussion about neurological health, player care and what the league owes retired players—or simply a moment appreciating both careers.Can Deebo Samuel actually recreate the old magic in San Francisco? The surface conversation is whether he helps the receiving corps. The deeper tangent is whether returning to a familiar coach and system can reverse years of physical decline and organizational tension.Would Aaron Donald's return make the Rams unfair or merely famous? Donald, Garrett and the Rams' upgraded secondary look terrifying on paper. The tangent is whether a retired interior lineman can return directly to championship-level football conditioning.Why are teams extending defensive stars earlier than quarterbacks? Philadelphia moved decisively with Carter, while Tampa allowed both the Mayfield and Vea situations to become public. Is defensive value becoming easier for teams to price, or are quarterbacks simply asking for numbers teams no longer want to guarantee?Is Pittsburgh protecting Aaron Rodgers or changing its identity? Mike McCarthy eliminated live tackling from training-camp drills in his first year replacing Mike Tomlin. That can be a simple injury-prevention story or a larger conversation about whether the Steelers are no longer interested in performing toughness for tradition's sake.TouchdownOrTurnoverDeebo back to San Francisco on a one-year deal.The Eagles paying Jalen Carter before his leverage grows further.The Rams encouraging an Aaron Donald comeback.Rodgers announcing his retirement plans before the season.The Saints giving Chris Olave four years and $132 million.Cleveland making Denzel Ward the NFL's highest-paid defensive back again.The Browns extending Grant Delpit for three years and $48 million.Tampa refusing to meet Baker Mayfield's current valuation.Indianapolis refusing to trade Anthony Richardson cheaply despite his reported request to leave.The Rams drafting Ty Simpson rather than spending that first-rounder on immediate help.The NFL reducing the gap between the combine and free agency to one day beginning in 2027.FairOrFadeBrandon Aiyuk versus the 49ers: Aiyuk has taken his complaints to social media, pitched himself to Washington and continued escalating the split publicly. Is he fairly exposing how San Francisco handled him, or trying too hard to manufacture his preferred exit?Baker Mayfield versus the Buccaneers: Mayfield says the organization's offers made him feel disrespected and undervalued. Is that fair after what he has done for Tampa, or should the team be cautious about committing approximately $50 million annually?Vita Vea versus the Buccaneers: Vea requested a trade after unsuccessful contract efforts, and Mayfield publicly supported him. Is this a player correctly using his remaining leverage, or a veteran trying to force Tampa into paying for past production?Josh Allen versus critics of Buffalo's Nickel City uniforms: Allen told people to stop hating on the new alternates. Fair defense of a fresh look, or fade because the uniforms really are that bad?Ja'Marr Chase versus his own teammates: Chase ripped off and threw a teammate's helmet during a camp confrontation, then framed the incident as the competitiveness he wants from the defensive backs. Fair football intensity, or an unnecessary escalation from a team leader?Trey McBride versus Cardinals fans: McBride walked back his previous claim that there are “no Arizona fans in Arizona.” Was the original comment an honest observation, or disrespect toward a fan base already tired of being mocked?

Send us Fan MailEXCLUSIVE BOOK BONUSES Exclusive: Get CONNECTED and receive $247 in limited-time bonuses designed to help you apply the action items that Martha will discussed:GET MARTHA'S BOOK + LIMITED-TIME BONUSES:CONNECTED: Love, Loss, and the Unseen Forces Behind Chronic DiseaseGet your copy + $247 in free bonuses:→ http://biotiquest.com/bookbonus Amazon Digital Book Link:  https://a.co/d/0fId6WlEB&N Paperback Book:  https://www.barnesandnoble.com/w/connected-martha-carlin/1149968253Connect with Martha:Blog/Substack: https://marthasquest.substack.com/Website: https://biotiquest.comThe BioCollective: https://www.thebiocollective.com/Instagram: https://www.instagram.com/biotiquestEpisode brought to you by: AG1 - Your daily dose of nutrients in one amazing tasting drink Get yours along with free travel packs at www.drinkag1.com/funcitonallyautoimmune and byCesira Your home for authentic Italian Extra Virgin Olive Oil, and Mediterranean Living. Grab your bottle, or join us for an immersive Italy Retreat www.cesiraoliodoliva.comAthletic greens is a non-negotiable part of my daily routine. With 75 absorbable vitamins and minerals in just one scoop a day, I have increased my energy, improved my immune function and so much more. To get your own AG at 20% off go to www.athleticgreens.com/functionallyautoimmune Order now for a free vitamin D3/K2 supplement and 5 free travel packs!Support the show

The WNBA dismisses Angel Reese & Paige Bueckers' betting scandal as a joke, Packers legend Ahman Green reveals he has Parkinson's disease, Myles Garrett speaks about Aaron Donald's 'difficult' comeback decision, and prosecutor claims Anthony Smith tried to hit his wife with his car after a heated argument. Learn more about your ad choices. Visit podcastchoices.com/adchoices

https://www.drsharnael.com/ tell me about your new book what inspired it what is iboga how is it different the ibogaine how has it helped people is it safe ? what do you have coming up ? 1. Why is it important to consciously connect with Nature and recognize that She is a living sentient being? 2. What are the health benefits of being in a felt communion with Nature? 3. A few highlights from my own journey into Nature Reunion 4. Some easy but powerful practices for Nature reconnection 5. Our body as part of Nature—treating ourselves with mindful self-compassion and respect. 6. Coming Home to Nature means being deeply aware of, and connected to, the wisdom and healing power of Mother Earth and our own bodies. 7. My book, both kindle and paper back will be released on August 1st. The kindle e-book version is available now. What if the roots of suffering are deeper than we'vebeen taught? Is there hope when hope for the hopeless? When life fractured in ways she could notintellectually solve, Dr. Sharnael — naturopathic physician and consciousnessteacher — was called beyond logic, beyond theology, beyond science — intodirect encounter. Enter Iboga. Often referred to as “Grandfather Iboga” and known asthe “Mount Everest of plant medicines,” this“The Truth Hunter,” African root functions as a powerful neurological andpsychological interrupter, disrupting entrenched patterns of illusion,compulsion, and genetic survival programming. In this deeply personal journey, Dr. Sharnael shareshow one of the most intense and misunderstood plant medicines on earth became amirror — illuminating unresolved grief and the unconscious patterns shapingidentity, while guiding her from darkness and sorrow into renewed hope,courage, love, and joy. At a time when suicide rates remain high and opioidaddiction devastates families worldwide, Iboga has drawn attention for itsunique interaction with opioid receptors and its growing exploration inaddiction recovery research. It is also being studied for its potential relevance indepression, PTSD, traumatic brain injury, multiple sclerosis, Alzheimer's,Parkinson's disease, Lyme-related neurological complications, and other complexnervous system disorders. Traditionally, the root bark has also been examinedfor antimicrobial and antiparasitic properties. Part personal journey, part clinical guide, GrandfatherIboga serves readers seeking Truth, transformation, and understanding. Written by a doctor who became the patient, this bookis for anyone navigating loss, addiction, neurological complexity, and foranyone seeking Divine Truth where conventional paths have fallen short I almost didn't write these books. It would have beeneasier to stay quiet. Easier not to speak publicly about grief. Trauma. Plantmedicine. Consciousness. Easier to protect my reputation than enterconversations that are complex, controversial, and often misunderstood. But silence felt dishonest. And some stories are meant to be told. Today, I am honored to officially announce the releaseof two deeply personal and professional works: The Science of Miracles Workbook and Grandfather Iboga – A Personal Journey Through Grief,Trauma Healing, and Soul Transformation These are not just books. They are lived experience. Together, these two books represent the bridge I havealways stood on — science and spirit, clinical understanding and consciousness,measurable biology and Divine design. There were moments I nearly stayed silent. But if even one person finds hope in these pages… itwas worth it. Presales are now open. You can order both books here:https://www.drsharnael.com/shop The Science of Miracles Workbook This workbook was born from years of studyingconsciousness, neuroscience, biofeedback, and the unseen laws that shape ourphysical reality.

Cells are full of molecules. Some are very large, such as proteins and DNA. Studying specific molecules or organelles in isolation is challenging. Elizabeth New makes sensor molecules which allow specific cell contents to fluoresce when viewed with a microscope. The aim is to see the effects of diseases and drugs on cells. Her methods can be applied to neurodegenerative diseases such as Parkinson's Disease, cancer and diabetes and show molecules which cause harm and bring on ageing. There are opportunities to look for predictors of disease and test drugs. Elizabeth New is speaking from the SESAME synchrotron in Allan, Jordan where she is on secondment.

Bump and Stacy take a ride on the hype train -The Mariners get a series win against the Dodgers- Emerson Hancock pitched his last game in a Mariners unifor- Leonard Williams will lead the Seahawks in sacks this year- Michael Arroyo is a Mariner tonight AND past August 3rd- Rushing water is safer than still water //  Seahawk running back: Ahman Green announced he was diagnosed with Parkinson’s disease in the last year - Puka Nacua spoke to the media for the first time at Rams camp. - Baker Mayfield is airing out his frustrations with the Buccaneers not meeting his deadline for a new deal - Michael Penix still hasn’t been cleared from his ACL injury and he says it might be another month before he’s allowed back on the field // The takeaways from the interview with Dante Fowler.  

In this late-night episode, Walter Sterling and his "Midnight Misfits" unpack their lingering Covid-19 grievances, taking aim at Dr. Fauci's recent Senate hearings, mask mandates, and the controversial use of remdesivir and ventilators. Walter shares his own medical saga, claiming that the Covid vaccine gave him temporary "pharmaceutically induced Parkinson's" and made all food except plain oranges and unadulterated steak taste like rotting garbage. Plus, New Mexico broadcaster Eddie Aragon drops in to unravel a wild conspiracy theory involving Gene Hackman's Santa Fe estate, a tragic hantavirus outbreak, and alleged secret Illuminati tunnels hidden beneath his house. Throw in callers sharing quarantine horror stories, political rants, and one incredibly generous listener offering to fund Walter's vacation to Bermuda on his credit card, and you have a classic, chaotic hour of talk radio.

What if Parkinson's disease begins years—or even decades—before a diagnosis? In this episode of The Coach Debbie Potts Show, Debbie sits down with entrepreneur, researcher, and author Martha Carlin to discuss her new book, Connected, and the remarkable 24-year journey that began after her husband John's Parkinson's diagnosis. Together they explore the patterns, clues, and correlations that led Martha to investigate the gut microbiome, chronic stress, environmental toxins, glyphosate, glycocalyx health, the gut-brain connection, and why chronic disease may be the result of multiple interacting stressors rather than a single cause. This conversation goes beyond Parkinson's. It's about learning to ask better questions, recognizing the body's early warning signs, and understanding how resilience, metabolic health, and the microbiome may influence healthy aging. In this episode you'll learn: • Why Parkinson's may begin years before diagnosis • The connection between the gut microbiome and brain health • Early clues that are often overlooked • Environmental and lifestyle factors that may influence long-term health • Why restoring safety, resilience, and metabolic balance matters • How a systems biology approach differs from treating symptoms alone Learn more about Martha Carlin and her work:

Building a cell therapy company is hard. Building a genetically engineered iPSC therapy for the brain, on a preclinical budget, is one of the hardest translational problems in biotech. Every experiment has to move the program closer to an IND, or it's motion without progress.That's the operating constraint Bilal Fares faces as CEO and co-founder of AzureCell, the University of Geneva spin-off engineering neuroprotective iPSC neurons for Parkinson's disease. In Part 2, he walks through how his team decides what to build, where AI and synthetic biology genuinely accelerate a CMC roadmap, and the four founder lessons he wishes he'd internalized earlier, including his conviction that scientists who use AI will replace those who don't.Topics discussed include:Strategies for prioritizing experiments and narrowing focus with limited resources (03:33)How business opportunity validation programs helped define a product roadmap (04:08)Integrating AI and synthetic biology into research programs—and where these tools do, and don't, accelerate development (05:07)Building a cell therapy platform for personalized approaches in neurological diseases beyond Parkinson's (06:38)Lessons learned in biotech leadership and why tackling big problems matters (08:08)Key advice for aspiring biotech entrepreneurs: kill your own solutions quickly, and learn from others (09:27)The importance of having a strong team and how a powerful mission attracts top talent (12:21)AzureCell's near-term plans and future goals, including upcoming fundraising and R&D milestones (13:30)Smart insight: What separates successful biotech ventures from the rest? According to Bilal Fares, it is not just technical skill but mindset. First, choose a problem large enough to be worth the struggle. Second, try to “kill your solution as fast as possible”—engage experts, enter competitions, and seek brutal feedback early so you can pivot, improve, or abandon as needed. And finally, plan with the end (approval, patients, impact) always in sight.If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities.Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung WooEpisodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta LeeEpisodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale BernatchezEpisodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeConnect with Bilal Fares:LinkedIn: www.linkedin.com/in/b-fares AzureCell website: www.azurecell.co Email: info@azurecell.coSupport the show

In case you missed it, the Megadeth show at the Southside Oktoberfest grounds tomorrow night is moving down the street a bit & is now happening inside the La Crosse Center. Find all the info here. Obviously, the threat of rain with some possible lightning and heavy winds can seriously affect any outdoor event, so moving the show to the Center makes a ton of sense. Also in the news this morning, a nationwide recall on eyedrops, accusations by multiple women against Jared Leto, the Mayor of St. Paul is being investigated, Dr. Fauci pleads the fifth, Afroman is suing, and a ban on Roomba vacuums. In sports, the Brewers got shellacked by the Giants last night, an update on yesterday's training camp injuries, the latest on Mia Bieniemy, and Ahman Green announces that he's got Parkinson's. Talked about what's on TV & streaming today/tonight, and discussed Ben Affleck's big win on "Who Wants to Be a Millionaire" last night. If you're looking for something cool to do this coming Halloween, you might want to go to Universal Studios. Three women in a car flew off an overpass and ended up landing upside-down & trapped in the vehicle until a bunch of strangers came to their rescue. And a young lifeguard is a hero after saving a young boy from drowning. It's Hypothetical Thursday and with Jean in Boston, I asked you the question this morning: "If the Purge was real, would you participate or lock down with your family/friends/neighbors?" Office Cora also joined me just after 8am to talk about what she's up to in the 715 this weekend…and her hypothetical question for me was: " " Elsewhere in sports, Macklin Celebrini signs a massive contract, Plaxico Burress compares his time in prison to playing with the Jets, and a professional golfer ends up in the wrong country after looking for some Korean BBQ. And in today's edition of "Bad News with Happy Music", we had stories about a woman who Googled "Does God Forgive Murderers" before actually killing someone, Fireball's new sneakers, the robot that was supposed to help teachers at a school in NY isn't happening afterall, a man accuses his partner of cheating on him with a very specific sex toySee omnystudio.com/listener for privacy information.

Season 26, Episode 19 - Shaun Boyce, Bobby SchindlerSummaryIn this episode, Greg Johnson from My Profit Professionals discusses how small business owners in racket sports can build financial systems that make profitability intentional rather than accidental. Greg shares practical strategies for managing cash flow, overcoming mental barriers around money, and why having an external advisor delivers ROI that most business owners never expect.Key TopicsFinancial systems for small business ownersProfit First methodology and cash flow managementParkinson's Law and why revenue disappears as fast as it comes inOvercoming ego and mental barriers in businessThe value of accountability and human coachingBehavioral economics in business growthKeywordsracket sports business, tennis business, profit first, small business finance, financial coaching, teaching pro business, profitability, cash flow management, Parkinson's Law, business accountability, My Profit Professionals, Greg Johnson, GoTennis podcast, ARA, American Racket Sports AssociationSound Bites"Most people never get taught how money should actually flow through a business.""Bet on yourself and take the leap.""Having a human coach is worth the investment."Full YouTube Video: https://youtu.be/_rQEqN5_If0Learn more about Greg: https://www.linkedin.com/in/greg-johnson-cpa/Contact Our HostsShaun Boyce, RSPA: shaun@americanracketsportsassociation.com | https://americanracketsportsassociation.com/Bobby Schindler, RSPA: schindlerb@comcast.net | https://letsgotennis.com/windermereGeovanna Boyce: geovy@regeovinate.com | https://regeovinate.com/GoTennis Website: https://letsgotennis.com/Learn more about the Marc Kaplan Media Excellence Award we (the GoTennis! Podcast) won from USTA Georgia: https://letsgotennis.com/captivate-podcast/gotennis-podcast-wins-the-marc-kaplan-media-excellence-award/Join Our CommunityCheck out the GoTennis! Atlanta Facebook page for deals, updates, events, podcasts, news, stories, coach profiles, club information, and more.Support the ShowDonate Directly: https://gotennispodcast.captivate.fm/supportCrypto Donations: Get into crypto with https://coinbase.com/join/PEWRLWK?src=referral-linkStart Your Own PodcastConsidering your own podcast? We recommend Captivate: This podcast is hosted by Captivate, try it yourself for free.

Vous cherchez une conversation qui fait du bien, qui est lumineuse et qui nous ramène à l'essentiel? Une conversation qui a l'effet d'une leçon de vie et d'espoir? Dans cet épisode, on reçoit Stéphanie Boisvert, maman, entrepreneure et docteure en psychologie, qui partage avec une grande douceur son parcours marqué par un diagnostic de Parkinson précoce… découvert à 34 ans alors qu'elle était enceinte de son deuxième enfant. On plonge avec elle dans : le bouleversement de recevoir un diagnostic aussi inattendu en pleine maternité, la réalité très peu connue du Parkinson chez les jeunes mamans, l'importance de la bienveillance envers soi (et de pardonner même ses pensées les plus difficiles!), le pouvoir de s'entourer d'un bon réseau et de parler ouvertement de nos épreuves, la résilience, l'art comme outil de mieux-être, et la reconquête du moment présent malgré l'incertitude. Cet échange est un vrai baume pour celles qui vivent ou ont vécu une épreuve, ou pour toutes celles qui souhaitent réfléchir au sens de la maternité et à ce que ça veut dire être “assez”. Un épisode plein de douceur qui, on l'espère, vous fera autant de bien qu'à nous!   Pour recevoir votre dose hebdomadaire de réconfort directement dans votre boîte courriel, c'est ici!    Vous êtes un.e professionnel.le qui travaillez auprès des parents? Découvrez notre centre de formations continues :  CVM Formations!   COMMENT CONTRIBUER AU SUCCÈS DU PODCAST ÇA VA MAMAN? Suivre le podcast Afin de ne manquer aucun épisode, cliquez sur le bouton "+Suivre" ou "S'abonner" dans le haut de votre plateforme préférée. Commentaires Saviez-vous que les commentaires jouent un rôle important dans l'algorithme des plateformes de podcast? Si vous nous laissez un commentaire, non seulement il nous aidera à rester connectée avec votre vécu, mais il permettra à plus de gens de connaître notre podcast et donc nous permettra d'aider encore plus de mamans. Si vous pouviez prendre 2 minutes de votre temps pour nous laisser un petit mot, ce serait immensément apprécié! Médias sociaux Si cet épisode a résonné pour vous et qu'il vous a fait du bien, n'hésitez pas à le partager à une amie ou une maman qui en aura bien besoin. Vous pouvez aussi le partager sur les médias sociaux en prenant soin de nous identifier @cavamaman afin que nous puissions vous remercier et repartager à notre tour. Toutes les petites actions comptent vraiment et nous aide à garder le podcast en vie! Merci! Jess et Lory

Could multiple sclerosis one day be detected before symptoms appear? And if so, should we be actively screening people who are at higher risk? In this episode of the ECTRIMS–MS Journal collaboration series, host Prof. Anneke van der Walt, Controversies Editor at the Multiple Sclerosis Journal, is joined by Prof. Helen Tremlett (University of British Columbia) and Prof. Ruth Ann Marrie (Dalhousie University) to debate one of the most important emerging questions in MS research. Helen argues that targeted screening should begin now—but only within carefully designed research studies—to better understand how MS develops before clinical symptoms appear. Ruth Ann argues that while prevention is the ultimate goal, the science, ethics and healthcare systems are not yet ready for widespread screening. Together they discuss: ·      Whether MS is entering a new era of prevention research ·      What lessons can be learned from Parkinson's disease and radiologically isolated syndrome (RIS) ·      The ethical and psychological impact of identifying people at risk before symptoms develop ·      How screening programmes could improve—or worsen—health inequalities ·      What research is still needed before screening could ever become part of routine clinical practice Although they argue opposing positions, both experts agree on one important point: preventing MS is an achievable ambition—but only if research proceeds carefully, ethically and equitably. This MS Journal Controversies article series has been made open access for the next month for ease of reading. "Yes" – High-risk populations should be screened for MS "No" – High-risk populations should not yet be screened for MS "Commentary" – High-risk populations should not yet be screened for MS Note: This episode is part of the MS Journal Controversies in MS series, where experts debate opposing viewpoints on important unresolved questions in MS research. The positions argued do not necessarily represent the authors' personal opinions, but rather present the strongest evidence supporting each side of the debate.

Heather Butchen is a care partner for her husband Jeff, who was diagnosed with early-onset Parkinson's disease at 51 years old. Over the past decade-plus, Heather has navigated the evolving challenges that come with a progressive disease — and a few years ago, she and Jeff reached a major milestone when he underwent Deep Brain Stimulation surgery, known as DBS. In this episode, Heather shares practical wisdom from her caregiving journey. We talk about how she keeps a dedicated medical journal to stay organized across doctor's appointments and support group meetings, and how those notes proved invaluable when they were ready to explore DBS surgery. Heather also shares how she and Jeff co-founded a Parkinson's support group back in 2014 that is still going strong today. She shares her "do it now" philosophy when it comes to travel, including smart tips for navigating airports with a hidden disability using the Sunflower Lanyard program. She talks candidly about the creativity it takes to keep a care partner engaged in physical activity — and why boxing has been an ideal activity for Jeff. We also get into the tender aspects of their partnership — how they've simplified family gatherings to reduce stress, how they use conversation cards at dinner to reconnect and go deeper after 31 years of marriage, and what it has looked like to rediscover each other as their kids have grown and moved out. And we absolutely talk about Heather's own self-care routines, which include walking catch-ups with friends, Pilates, Mahjong, and her favorite snacks. Show notes with product and resource links: https://bit.ly/HHCPod233 Receive the podcast in your email here: http://bit.ly/2G4qvBv Order a copy of Elizabeth's book Just for You: a Daily Self Care Journal: http://bit.ly/HHCjournal For podcast sponsorship opportunities contact Elizabeth: https://happyhealthycaregiver.com/contact-us/ The Happy Healthy Caregiver podcast is part of the Whole Care Network. Rate and Review the podcast: https://bit.ly/HHCPODREVIEW

On the Tip of My Tongue: Jonathan Hirons on Aphasia, Advocacy, and PodcastingThis episode, Marv sits down with Jonathan Hirons, host of the podcast On the Tip of My Tongue, to talk about aphasia — a communication disorder that affects language but not intelligence or memory — and how it shaped his life and work.Jonathan shares the story of the sudden stroke that left him with aphasia, the speech and language therapy that followed, and the vital role his wife played early on using flashcards to help rebuild his vocabulary. He and Marv discuss why aphasia remains so poorly understood despite affecting more people than Parkinson's disease, and why groups and community support make such a difference for people relearning to communicate.The conversation also traces how Jonathan's aphasia documentary evolved into a podcast, why he brought on co-host Rob Edwards to handle scripted segments, and how the show balances lived experience with expert insight. They wrap up comparing notes on production workflows, episode artwork, and the "teaser hook" technique both shows use to draw listeners in.In This Episode● What aphasia is, and why it's known as a "hidden disability"● Jonathan's personal story: sudden onset, hospitalization, and diagnosis● The road through speech therapy and relearning to read, write, and speak● Why community groups are key to rebuilding confidence● How a documentary film became a podcast● Behind-the-scenes: recording with Zoom, editing in Reaper, publishing via Buzzsprout● The importance of podcast artwork and episode "teasers"● Where to find On the Tip of My Tongue and how to support the showLinks & ContactOn the Tip of My Tongue: tipofmytonguefilm.comEmail Jonathan: hello@tipofmytonguefilm.comFind Jonathan on Instagram, Facebook, and LinkedInPods Like UsContact: podslikeus@gmail.comAll links and socials: themarvzone.org

Avanzan trabajos de recuperación de cuerpos en Pasta de Conchos ¿Sin plan? La Sedema te invita a sus actividades recreativas EU intensifica operativos antiinmigrantes en aeropuertos #grc

Tom Cruise and Brad Pitt's kids are making headlines—and we did not see this coming! We break down the latest celebrity family drama, the buzz around the new Spider-Man starring Tom Holland and Zendaya, Purple Rain heading to Broadway, The Thomas Crown Affair, and why A League of Their Own is still a classic. Plus, Julia shares a wedding update (eyelashes, makeup, and shoes!), we discuss Carly Simon's heartbreaking diagnosis and first album in 18 years, recommend book The Anniversary by Alex Finlay, and Lori shares her TV obsession with Ride or Die on Prime Video. We also have a Louvre heist update, Buck Moon chat, and welcome Anthony Bosca from InVision to talk eyewear fashion, Julia's mother-of-the-groom look, their shop dog June Bug, and the new rules for turning 60.00:00 - Introduction and audience feedback highlights 02:10 - Celebrity children changing their names: Suri Cruise and Brad Pitt's kids 07:20 - The explosive new "Spider-Man" movie and reviews 08:48 - "Man on Fire" TV adaptation and streaming series favorites 10:21 - The current heat wave and outdoor summer adventures 11:27 - Celebrating the buck moon: the energizing full moon of August 12:24 – Mother-of-the-groom Update: Eyelash and makeup trends 14:49 - Broadway updates: "Purple Rain" 17:18 - The remake of "The Thomas Crown Affair" starring Michael B. Jordan 18:43 - "A League of Their Own" still holds up! 23:52 - Carly Simon's health update and her new album after Parkinson's diagnosis 25:23 - Recent great reads: Alex Finlay's "The Anniversary" 26:20 - Streaming hits: "Ride or Die" 29:19 - "Man on Fire" TV series and other crime dramas to binge 42:22 - Louvre's Apollo Gallery heist history and the significance of France's crown jewels 47:37 – Anthony Bosca joins from InVision and the art of picking the perfect frames THANK YOU TO OUR SPONSORS:InVision Distinctive Eyewear: https://www.invision-optical.com/Borton Overseas: https://www.bortonoverseas.com/loriandjulia/Twin Cities Closet Company: https://www.tcclosets.com/ CONNECT WITH USInstagram: @loriandjuliaTikTok: @loriandjuliaListen on Spotify/Apple Podcasts: loriandjulia.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Two years after researchers identified ReNU syndrome, where are we now?   In 2024, two independent research teams identified the genetic cause of ReNU syndrome, a rare neurodevelopmental condition affecting thousands of people worldwide. The discovery marked the beginning of a new chapter for families searching for answers and opened up exciting new avenues for research.  In this episode, host Sharon Jones revisits the story to explore what has happened since that breakthrough. She is joined by: Professor Nicky Whiffin, Associate Professor and Wellcome Career Development Fellow at Big Data Institute and Centre for Human Genetics, University of Oxford Christina Cox, Co-founder of ReNU Syndrome UK and parent of a child with ReNU syndrome Dr Ana Lisa Tavares, Clinical Lead for Rare Disease at Genomics England Together, they discuss how researchers around the world have built on the original discovery to deepen our understanding of ReNU syndrome, why studying the non-coding regions of our DNA is revealing previously unknown rare conditions, and how collaboration between researchers, clinicians and families is accelerating progress. They also explore how the growing ReNU community is supporting newly diagnosed families and what the future could hold for new treatments.  Links:  Previous episode detailing the discovery of ReNU Syndrome  ReNU Syndrome UK's website  Original research paper from Nicky's team in Oxford  Original research paper from the team based in New York   “It's been only two years since our paper came out about this, and in that time, there are now patient family groups that have been set up all around the world. There is the one in the UK led by Christina and the others. There's the one in the US that's led by a group of four women, and there are ones in France, Spain, like, literally all around the world. And all of these groups are also somewhat coordinated. The leads of these groups meet with each other. They've organised meetups. I've been to ones in the US, the UK, and in France. So the fact that they can mobilise all of that and create such a community so quickly is absolutely incredible.”  You can download the transcript, or read it below. [00:00:00] Sharon: In 2024, two independent research teams identified a genetic cause of a rare neurodevelopmental condition affecting thousands of people around the world. Since then, that initial groundbreaking discovery has grown into something much bigger, bringing together families, researchers, and clinicians, and building a clearer picture of what we now know as ReNU syndrome.  [00:00:26] Sharon: Welcome to Behind the Genes, the podcast that covers everything from cutting-edge research to real-life stories in genomic healthcare. I'm Sharon Jones, and in today's episode, we're looking at what's happened since that discovery, what researchers are continuing to learn, and what the future could hold for people living with  ReNU Syndrome and their families.  [00:00:46] Sharon: To help us understand more, I'm joined by Professor Nicky Whiffin, Christina Cox, and Dr. Ana Lisa Tavares. So, two papers were published around the same time for this condition. To start us off, Nicky, you worked on one of these papers. Could you explain how this journey first began?   [00:01:05] Nicky: Yeah, so this was two years ago now, back in early 2024, where two research teams, so us based in Oxford and a, a group based in New York, were both looking at the data within the National Genomics Research Library, and we both kind of somewhat simultaneously found that there was variance in this very, very small gene, it's called RNU4-2, were found in individuals with previously undiagnosed neurodevelopmental disorders.  [00:01:39] Nicky: And this was very, very striking because we initially actually identified the same single DNA change or mutation in 40 or so different individuals within the National Genomics Research Library, and we normally expect to see a whole host of different variants. We don't expect to see the same one.  [00:01:59] Nicky: So this was a really, really surprising finding. And it was through a collaboration, large scale collaboration across the world where we started contacting our other collaborators who have similar collections of patients who have been genome sequenced to ask if they had any individuals with DNA changes in this gene.  [00:02:17] Nicky: And we found some in the US, some in, in Australia, some in France and Germany. So very, very quickly built up this, this complete picture of variants in this gene, causing this rare neurodevelopmental disorder   [00:02:35] Sharon: of people finding it at the same time, what, what did that feel like?  [00:02:39] Sharon: Like, give us a ense of, like, that compelling, "We think we found something." What was that like?   [00:02:46] Nicky: I didn't believe it initially. You're always told when you're a scientist that if it looks too good to be true, it's, it's not true, and this basically lit up like a beacon. There's this particularly one DNA change that we found in, um, I think it was about 40 different individuals, and we don't really expect that to be the case.  [00:03:04] Nicky: We normally expect these genetic variants to be somewhat randomly distributed across the genome. So to find 40 individuals with exactly the same DNA change was very, very surprising. So initially, I didn't believe it. The whole team, including folks at Genomics England, spent a lot of time trying to check that these variants were real and tried to disprove the result, tried to find any other way in which any other reason why we would be seeing this.  [00:03:31] Nicky: And after a little while, we had to concede that we couldn't disprove it, so it must be true, and that, that was a very exciting moment.   [00:03:38] Sharon Jones: Was it the case that over in the States, the exact same thing was happening?   [00:03:42] Nicky: I think we found out when we were both speaking at the same conference, actually. So we didn't actually know that we, that we'd both come across the same result.  [00:03:49] Sharon: If you want to check out our previous episode on this initial discovery, you'll find a link to it in the episode description.  [00:04:00] Sharon: So Christina, tell us a bit about your situation, your family situation, and for our listeners, what ReNU is.   [00:04:05] Christina: So ReNU is, to us, is a family. We got a family when we got diagnosed with  ReNU. Beau - Arabella - already had other diagnosises, but people had always said to us, "Oh, there's something else. There's something else.  [00:04:20] Christina: We're not sure what it is, but there will be something." And then when we got  ReNU, it was like, "Oh, okay, amazing. What do we do? What is it?" Because there was only four lines on Wikipedia when we first got told about it, and there wasn't anything that, ourselves could find. So we kind of went onto Facebook and looked for groups and different people, and there wasn't really anything except for Jess in America.  [00:04:46] Christina: And then it grew, and then it kind of, we ended up finding more people in the UK and, like, all over. But for us, it didn't really change how we perceived Beau. It just made life easier. Like, knowing there was other families out there that we could find advice from and support from, and that we kind of knew what we had and going forward then, like, finding researchers and connecting with everybody.  [00:05:15] Sharon: Yeah. And for those who don't know, can you talk about what  ReNU is? Like, how does it affect Beau?   [00:05:20] Christina: So with Beau and  ReNU , it affects her with developmental delay. She's non-verbal. She's incontinent. She suffers for walking, so she can do a little bit of walking, but she needs a wheelchair It affects her mood swings.  [00:05:38] Christina: It just affects everything. Although she has it, she's still a happy, outgoing, very stubborn, just kind of "keep-going" child. But it affects her in everything, like eating, sleeping.   [00:05:51] Sharon: It sounds like life is, you know, very challenging on a day-to-day basis, lots of considerations. How did you feel when you finally got this diagnosis after years of wondering and waiting, not knowing?  [00:06:02] Christina: Finding out was, like, really emotional because it was like, "Oh, wow, so we have this diagnosis. Now what? What are we looking for? What's going to happen?" And then we were kind of like, "Oh, but there's not many people that had it." Because we found out in the August, so then it was trying to find people. But it has been life-changing to know that we're not on our own and that there is other people around.  [00:06:28] Sharon: Yeah, tell us a bit more about that. How did it feel to get that diagnosis?   [00:06:32] Christina: It was quite strange because our pediatrician rang us and said, "Oh, we've got a diagnosis. She's got RNU4-2." And we were like, "Okay, so what's that?" And she's like, "I don't really know. There's four lines on Wikipedia at the moment."  [00:06:46] Christina: She goes, "I don't like Wikipedia," but we still kind of... That was it. So then we went on a mission to find and look for where we could find support and find other families.   [00:06:58] Christina: At that point, I didn't know of anybody in the UK, and my husband found Jessica in America. What then, kind of, we had somebody to talk to, and then families in the UK kind of started appearing.  [00:07:09] Christina: So we ended up getting a whole network of people to bounce ideas off and talk about how it affects their children and what's for the future and things like that. It was really nice.   [00:07:22] Sharon: Yeah, yeah, I can imagine. So Ana Lisa, how do these findings contribute to a growing understanding of the condition?  [00:07:29] Ana Lisa: So this was an amazing discovery. Although we're finding new rare conditions quite often, not on this sort of scale. It was also an amazing finding because a lot of the genes that we know are associated with rare conditions are genes that encode proteins, and in the 100,000 Genomes Project, we were doing whole genome sequencing, and Nicky and her team were looking in the parts of the genome that don't encode for proteins.  [00:08:03] Ana Lisa: And so this was, uh, exciting from that point of view as well. So the vast majority of our genome, more than 98%, does not encode for proteins, but it's relatively unexplored. And if we think about our genome and the letter code that makes it up, which is the manual for how our bodies are built, and grow and function day-to-day.  [00:08:30] Ana Lisa: Those 3 billion letters, if you, if you printed them out in a 12 font regular print, it would stretch so far you could fly, I think, from London to Paris several times, maybe three times or something. And so, this actual gene is a very, very small gene, less than 150 of those letters. So again, it was incredible to find that by comparing across many, many different genomes in the National Genomic Research Library.  [00:09:00] Ana Lisa: Going back to your question about a growing understanding of a condition, it was a completely new condition, but it also opened up looking at other related genes and actually now more disorders that are being found, like RNU2-2 by colleagues in the US, and that might be one of the most common recessive genetic neurodevelopmental disorders.  [00:09:27] Ana Lisa: So it's really, really opened up this understanding about these types of disorders and also those non-coding parts of our genome and the power of collaboration and being able to look across many different whole genomes at the same time.   [00:09:44] Sharon: Yeah. And Nicky, you've been involved in much of this research journey.  [00:09:50] Sharon: What have been some of the biggest advances or learnings for you so far?   [00:09:55] Nicky: I think the biggest one is just how common, or how frequent, these disorders are. So what we discovered recently in terms of new genetic disorders were rarer and rarer conditions, and that's why we hadn't seen them before. But from going from looking at the protein coding genes to looking at these non-coding genes, we found something that was as frequent as disorders that were found in the early 2010s when we first had large-scale sequencing projects that looked at the protein coding genes.  [00:10:26] Nicky: So that was really, really surprising. And we now know there's this whole class of disorders. So RN4-2, this gene encodes this -- Well, it produces this small RNA that works in this huge molecular machine that is called the Splicer Zone, that mediates the processing of most of the other genes across the genome.  [00:10:50] Nicky: And there are lots of these little RNAs that work in this molecular machine that are called the small nuclear RNAs or the snRNAs And we now know that there are a whole multitude of different disorders associated with different ones of these spliceosomal small nuclear RNAs, and that's really incredible.  [00:11:09] Nicky: And for RNU4-2 itself, we also now know that there are, there's not just RENE syndrome, uh, which is a dominant disorder caused by chance de novo variants that are newly arisen in a child, but also a recessive disorder where a child inherits one, uh, gene mutation from each parent. And also another finding that there is a region of the gene where we find DNA changes that cause retinitis pigmentosa, so a retinal phenotype. So we now know a huge amount more about this single gene, but also all of this different class of genes or RNAs that work in the same molecular machine, uh, which is, is really fascinating biologically   [00:11:52] Ana Lisa: Vicky, while you were talking, I was thinking about the splicing and how a bit like this podcast recording, you're going to splice out the kind of extreme, the noise that wasn't supposed to be there.  [00:12:03] Ana Lisa: And actually, you could make slightly different versions of this podcast, couldn't you? And that's, that's what, what's happening in our bodies for a lot of our genes that, that the kind of output can be varied slightly.   [00:12:15] Sharon: So Christina, how has collaboration been involved across the community and with researchers?  [00:12:21] Sharon: You know, what sort of things have you been doing?   [00:12:23] Christina Cox: So it's amazing to have researchers that are so open and amazing to work with the families. So at the moment, we are just putting together like a panel to discuss questions from families, to then be able to answer families, to work very closely with the researchers for what things are happening and the progress within.  [00:12:47] Christina: It's just amazing to be able to work with researchers. They're just fantastic.   [00:12:52] Sharon: And from what I understand, like, you, you have a charity, don't you? Can you tell us a bit more about that and how that came about?   [00:12:58] Christina: So we have ReNU Syndrome UK, and it came about as there was a group of us parents that were like, we wanted to be able to support other families, knowing what it was like for us when we first started.  [00:13:12] Christina: It was very difficult. So we wanted to start a charity that can support families and signpost them, give them the opportunity to have family meetups once or twice a year, so we can work with scientists and specialists to keep everybody in the community, like the ReNU family, up to date. But being able to connect with so many families, because a lot of the doctors don't really know of ReNU Syndrome yet.  [00:13:46] Christina: So if we have a problem or a question, we put it in the WhatsApp group, and then somebody can answer it because they've been through it, or they, they've just asked the question. So it's just an amazing resource for everybody   [00:14:02] Sharon Jones: That sounds amazing, and it sounds like you've all obviously become experts by experience.  [00:14:04] Sharon: So, like you say, you kind of know more, you know, as the science develops, but you're living it every single day   [00:14:10] Christina: It's kind of, you go into the hospital and they're like, "Oh, what's ReNU Syndrome?" And then you're like, "Ugh." So, then you just have to say it all. But, and then it's kind of them bringing, teaching new people who don't know about it in the medical professional.  [00:14:26] Christina: We always give them the website so that they can go and then find, but being able to put more medical stuff on the website, it just helps everybody, and it's just broadening it out to as many people as possible. Because there's still a lot of people undiagnosed with RNU syndrome. It's, now it's easier to be signposted, but it's just keeping that connection.  [00:14:49] Sharon: Yeah. And, and from what I understand, it's got quite an interesting sort of origin of a name, RNU. Where did that... Do you know much more about where that came from?   [00:14:57] Christina: So, Nicky is the amazing person who, um, sorted the name and um, the origin. So, I'll pass that over to Nicky to answer that question because she's just amazing   [00:15:11] Nicky: Uh, so the name ReNU syndrome is an interesting story.  [00:15:13] Nicky: So, a lot of disorders or diseases are named after people. So, we all know Alzheimer's, Parkinson's, etc. And they're often scientists or clinicians that have spent a lot of time working on them. I think that's a little bit odd. I don't think it's the first thing that somebody should know about a disorder, is the name of somebody who's, who's worked on it or studied it.  [00:15:36] Nicky: But they're a very, it's very hard to find an alternative. When we were initially doing the press release around our paper, we had a quote from one of the mothers, Nicole Cedar, who has a, a wonderful daughter called Mia Joy, and she said that within their family, they like to refer to RNU, to RNU4-2 as ReNU, which is a really nice play on the RNU in the gene name.  [00:16:00] Nicky: So then I had an idea, okay, let's just change the spelling to make the, the kind of big R, little E, large N-U, then it would link to the gene name, but also would be a name that speaks to hope and the renewed hope of being given a diagnosis.   [00:16:13] Sharon: Yeah, absolutely, and that's a great, a great story and a great way of kind of making it feel like there is, there is always hope.  [00:16:20] Sharon: So, you know, Nicky, you're now part of the patient community. In a way. You know, so how does it feel to be on that other side of it from that sort of research perspective and now kind of, you know, in that, in that community?   [00:16:34] Nicky: It's amazing. I've got a new family as well. It's not, not just Christina and everybody.  [00:16:39] Nicky: I kind of, I'm a, a basic scientist. I'm not a clinician. Up until this point, we've always been one or two steps removed from actually interacting with the families themselves. Um, so my life has changed an awful lot over the last couple of years, uh, where now, um, I kind of talk to Christina or the folks in the US, really regularly, kind of on a weekly basis.  [00:17:02] Nicky: Um, so that's really different. And I just kind of want to highlight just what these families have achieved. So it's been only two years since our paper came out about this, and in that time, there are now patient family groups that have been set up all around the world. There is the one in the UK led by Christina and and the others.  [00:17:26] Nicky: Um, there's the one in the US that's led by a group of four women, and there are ones in France, Spain, like, literally all around the world. And all of these groups are also somewhat coordinated. The leads of these groups meet with each other. They've organised meetups. I've been to ones in the US, the UK, and in France.  [00:17:46] Nicky: So the fact that they can mobilise all of that and create such a community so quickly is absolutely incredible. And they've got families, they've got so many researchers that are interested in the cause. They're interacting with the pharma companies. They've upskilled themselves to learn so much about genetics.  [00:18:04] Nicky: And it's just an absolutely incredible thing to watch. They're so, so inspiring.   [00:18:09] Sharon: And from what I understand, Christina, you feel, you know, very passionate about Nicky in the same way, about your paths crossing in this way.   [00:18:16] Christina: Oh, my, yes. Every time I see Nicky, I've met her a couple of times, like, in person now, I just cry.  [00:18:22] Christina: I literally, we saw her at the UK meetup, and she walked in the door, and that was it. I was done. I was like, it's just meeting somebody who has changed so many lives and brought a community to other families. It's just amazing. And the support that Nicky's giving us weekly, daily, is just amazing. It is just life-changing for all of us.  [00:18:49] Sharon Jones: It's such a powerful connection. So Ana Lisa, why is collaboration between researchers, clinicians, and families so valuable in the rare disease research space? You know, and what role do large scale research projects and data sharing play in discoveries like this?   [00:19:06] Ana Lisa: Collaboration is completely incredibly valuable and for progress in the rare disease space where there's just so much still to learn.  [00:19:16] Ana Lisa: So more than half of patients and families where, uh, they're seeking a potential diagnosis, we're not yet able to, to find one, and there's so much yet that we still need to learn, and collaboration in so many different spaces and directions and across different spheres enables this progress. So for example, the fact that we have a really connected, uh, National Health Service and really close working between the NHS and Genomics England so that we can, for those patients and families that, that consent to their de-identified data being shared in the National Genomic Research Library, be able to work with many, many different researchers, uh, whether they're academic, institutions, industry, and try and find all the patients that could benefit from a new diagnosis and, uh, potentially new therapies in future clinical trials.  [00:20:21] Ana Lisa: And without that collaboration, it would be really, really hard to find all those people So because we sort of have a clinical research interface where we can go back to clinical teams and therefore to patients and families, even if there's a really, really ultra-rare condition with very few people known to have it that could be under different specialties in different regions, we would be able to contact their clinical team.  [00:20:51] Ana Lisa: So I think that, that collaborative working with the NHS is really powerful across researchers worldwide. Like in this example where a group in Oxford and a group in US were able to make this finding and then all the other findings that are coming from it. And really, without being able to compare across thousands of genomes, one wouldn't have been able to see this, this particular signal and see that there were more than 100 patients, and that was really powerful.  [00:21:20] Ana Lisa: If you just had one genome, you could never have made this novel discovery. I think the other thing is that, and Nicky will say that, you know, she, she then contacted her collaborators who also had access to, to, to data that had been shared by other families and could compare. And again, it's a whole sort of network across the globe.  [00:21:41] Ana Lisa: And we know that there are going to be many more diagnoses to be found. But also, um, I think collaboration will allow us to find new, new treatments. So if we can start to design treatments that target the DNA and RNA at, at source, then actually you could collaborate and say, "Well, this type of genetic mechanism could be targeted in the same way, potentially across even more than one rare condition and reach even more patients."  [00:22:13] Ana Lisa: And actually the power of collaboration across the ecosystem is that hopefully we'll end up with a pathway that can actually go from finding a new genetic finding, like Nicky and her team made, to helping all the people who could benefit from a diagnosis, having one, and then can one develop a treatment and get it to as many patients?  [00:22:42] Ana Lisa: And, and I think that will really demonstrate the power of collaboration.   [00:22:47] Sharon: Yeah. Absolutely, and it can only, you know, benefit those families who have to wait such a incredible amount of time.   [00:22:55] Ana Lisa: There's been such a diagnostic odyssey, and as more diagnoses are made, it becomes obvious that there's, uh...  [00:23:03] Ana Lisa: and it was, it's already well-described, the therapeutic odyssey. Um, but hopefully these sort of novel understanding of our genome and opening up new biological avenues to treat, um, hopefully will also enable many more new treatments to be developed.   [00:23:21] Sharon: Absolutely, and that is the key word there is, is that hope.  [00:23:24] Sharon: So, so looking ahead, Nicky, what developments are you most hopeful about over the next few years?   [00:23:31] Nicky: That's a difficult question. There's so much, so much happening. One thing is that we are gearing up to do large scale studies across the world to understand more about the progression of ReNU. So you might call them large scale natural history studies or just large scale profiling studies where we can do a range of different tests on ReNU patients and, and monitor them over time.  [00:24:02] Nicky: So do those at regular, regular intervals over time so we can see what the progression looks like. And that's really important for trying to think about whether we can treat RNeU syndrome. And on that note, I'm very also excited about the potential for therapeutics. There's lots of people all around the world, both, uh, in academic settings, but also in pharma companies trying to work out whether this is something that we can treat.  [00:24:30] Nicky: There's some very promising early data to show that we can selectively remove the RNA containing the mutation from cells, uh, leaving the copy of the RNA that doesn't contain the mutation intact so that can do the correct function. And biologically, we think this should be an effective treatment.  [00:24:54] Nicky: Um, so we can do that in cells in a dish. We don't yet know whether we can do that in a patient with ReNU. Uh, but that's really, really promising early data. Um, so I'm very hopeful about where that, those studies might lead.   [00:25:08] Sharon: And Ana Lisa, what role will genomics continue to play in improving understanding and care for rare conditions like this?  [00:25:15] Ana Lisa: So following on from what Nicky said, I think the really big hope is that we will be able to develop many, many new treatments collaboratively across the world. And whether these are individualised treatments made for one patient but then shared because we can find perhaps other patients who could benefit from the same treatment, whether we understand the genetics better so that we can design treatments from the start that will work for a lot of patients.  [00:25:46] Ana Lisa: So I think there will be sort of fancier and fancier ways of targeting rare conditions. And right now we're in a phase where the ecosystem is trying to work out how could we make an end-to-end pathway with initiatives like the Rare Therapies Launchpad in the UK, and that's going to require truly collaborative working.  [00:26:08] Ana Lisa: No single organisation can do that. And I think having these incredible use cases will be really powerful for turbocharging the development of these pathways. And the hope is that once you've worked out how to do this across a range of different rare conditions, that one might reach a stage where one could do that a lot faster for many other rare conditions.  [00:26:35] Ana Lisa: Because at the moment they're so underserved in terms of treatments available and there's a huge gap between being able to make a genetic diagnosis and then having treatments. The big hope is that understanding the genetics better will help to open up new pathways to treatment. I do hope that we'll also understand other aspects.  [00:27:02] Ana Lisa: So for example, it might be that understanding the genetics better also helps us to understand different ways a condition might manifest in somebody, why it may be different from one person to another, why somebody might be more mildly affected and somebody perhaps more severely. And that might, may also help us to understand ways to treat a condition by getting, gaining these insights which are, are useful in and of themselves and may also lead to new therapeutic, uh, possibilities.  [00:27:36] Ana Lisa: I think that would be one of my hopes that a lot of these areas overlap and lead to real benefit for patients and families, that we can translate that hope into concrete improvements in treatment for rare conditions.  [00:27:57] Sharon: Do you have a sense of time, how long you think this could all take, that amount of collaboration?  [00:28:06] Ana Lisa: Yeah, and I think this is actually another reason why sometimes it's quite tricky to make progress in this area because being able to predict those timelines is notoriously difficult when you look back historically. I'd like to hope that we're on the cusp of having an explosion of novel treatments that can target DNA and RNA, for example, or treatments that target something in the underlying biology that we now understand that we didn't before.  [00:28:34] Ana Lisa: And I do think that there is going to be a big shift. But I think that the sort of confidence intervals around how big that range of time might be is very hard to predict. And that's why I think Christina and Nicky being able to share these stories and about their collaborative working really shines a spotlight on, on what could be done and how progress can happen.  [00:29:02] Ana Lisa: That's really exciting. The other day at a conference, someone from industry stood up and said, "Oh, actually, we set up a clinical trial in the UK because we knew there were patients who could benefit from our work in the National Genomic Research Library," and that was really exciting for us because that's what we want to do; move forwards the opportunities for treatment for patients.  [00:29:28] Sharon: And so finally, Christina, as a parent and member of this community, what are your hopes for the future, and what would you say to families who may still be searching for answers today?   [00:29:39] Christina: It is a long journey, but there is the support and the help out there. If you have any inclination that you think you might have ReNU, reach out to your paediatrician or your doctor to see if you can get your genetic testing done because it's fighting to get the test, to go to people and say, "I think this is what we may have. Can we look into getting it tested?" And reach out to other families and the website and things because it's all about community and supporting and helping people find that diagnosis.   [00:30:16] Sharon: Thank you, Christina, and we'll put the website in the episode description. A huge thank you to Professor Nicky Whiffin, Christina Cox, and Dr. Ana Lisa Tavares for joining me today and sharing their insights and experiences. To learn more about ReNU Syndrome, visit renusyndromeuk.org. If you'd like to hear more stories about the people, research, and discoveries helping to shape the future of healthcare, subscribe to Behind the Genes on your favourite podcast app.  [00:30:45] Sharon: Thank you for listening. I've been your host, Sharon Jones. Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan, and Katie Revell at Bespoken Media. 

Planning continues to come together for Findlay's proposed microtransit system... We get an update on the progress of this effort and what needs to happen next to bring it to fruition (at 15:26) --- To Your Health: Muscle tremors are one of the most common and well-known effects of Parkinson's Disease, but the two don't always go together (at 28:47) --- Around Town: Growing Hope in the fight against a disease impacting thousands of families... The Hancock County Parkinson's Network is holding their annual tulip bulb sale (at 41:29)

Horrifying day at the dentist and being scammed for thousands out of my bank account...Woke Cracker Barrel CEO steps down...Crazy entries in the fraud Dr. Fauci's daily diary...Carly Simon dealing with Parkinson's and skin cancer.https://mydeals.page/q7j8

Joining Kiri Pritchard-McLean this week is comedian Michelle Wolf who reflects on home births, Professor Stephen Wallace explains how old plastic bottles can be transformed into a form of Dopamine that can be used to treat Parkinson's disease, and Dr Matt Clarke demonstrates the power of medical collaboration in helping to identify and treat brain tumours.Best Medicine is your weekly dose of laughter, hope and incredible medicine. Award-winning comedian Kiri Pritchard-McLean is joined by a funny and fascinating panel of comedians, doctors, scientists, experts and historians to celebrate medicine's inspiring past, present and future.Each week Kiri challenges a panel of experts and a comedian to make a case for what they think is 'the best medicine'. Each guest champions anything from world-changing science or an obscure invention to an everyday treatment, an uplifting worldview, an unsung hero or a futuristic cure.Whether it's groundbreaking surgery, seaweed underwear, AI glasses to help people with dementia, horse therapy, sports, revolutionary gene therapy for Huntington's disease or yesterday's rubbish becoming tomorrow's medicines - it's always something worth celebrating.Hosted by Kiri Pritchard-McLeanFeaturing: Dr Matt Clarke, Professor Stephen Wallace and Michelle Wolf Written by Edward Easton, Jordan Gray, Kiri Pritchard-McLean and Ben RowseProducer: Tashi RadhaExecutive Producer: Ben WorsfieldTheme tune composed by Andrew JonesA Large Time production for BBC Radio 4

The Tim Conway Jr Show Hour with Mark Thompson Hour 2 (7.27) Mark’s getting married in a few days and just returned from a special trip with the love of his life, Courtney, to England and her ancestral homeland of Croatia, where her family history stretches back 500 years. Courtney jumps on the phone to share highlights, including seeing her favorite artist Ludovico Einaudi perform for the 30th time and catching the London theater production “1536” about Henry VIII and the beheaded Anne Boleyn. Swedish pop-rock duo Roxette has canceled their entire US tour, blaming expenses and logistics — though soft ticket sales may have played a role. Mark recently caught a downtown LA band whose singer sounded exactly like Taylor Dayne — only to discover the whole group, including the vocalist, were men in drag performing under the name Transatlantic. In sadder news, iconic “You’re So Vain” singer Carly Simon, 83, is battling both cancer and Parkinson’s disease. The daughter of a Simon & Schuster founder and an activist mother grew up in the Bronx and has become increasingly reclusive as her health declined. And one year after Dolly Parton lost her husband of 60 years, Carl Dean, her brother Coy “Denver” Parton has died at 82. With 12 siblings in the Parton household, it’s no wonder Dolly never had kids of her own. See omnystudio.com/listener for privacy information.

¡Siga y califíquenos en su plataforma favorita de podcasts para recibir notificaciones cuando salga un nuevo episodio! Cuéntenos que otros temas le gustaría que cubriéramos visitando parkinson.org/podcastencuesta.  Muchas personas asumen que los problemas para tragar, o la disfagia, solo ocurren en las etapas más avanzadas de la enfermedad de Parkinson (EP). En realidad, como estos cambios pueden desarrollarse gradualmente y aparecer antes de lo esperado, la detección temprana es fundamental. Saber qué señales buscar puede ayudar a las personas con Parkinson y a sus seres queridos a obtener el apoyo y la atención que necesitan.  En la parte 1 de esta serie de dos partes, hablamos con Martha Suárez Torres, terapeuta del habla y el lenguaje y aliado en el cuidado de su esposo con Parkinson, sobre cómo los cambios al tragar pueden afectar a las personas con la EP y cuándo es momento de buscar ayuda de un especialista. También comparte estrategias para reconocer cambios en casa, manejar la deglución de manera segura y explica cómo los familiares y seres queridos desempeñan un papel importante al informar cambios con el tiempo.  Manténgase atento a la parte 2, donde continuamos nuestra conversación con Martha mientras habla sobre cómo abordar los desafíos de comunicación al cuidar a alguien con Parkinson. Durante el episodio, Martha menciona un curso en línea sobre cómo entender el papel de la atención neuropaliativa para apoyar a un ser querido con Parkinson. Obtenga más información aquí, actualmente disponible en inglés. Recursos en español:  Lea nuestra hoja informativa sobre "el habla y la deglución (tragar) en el Parkinson".  Aprenda cómo puede ayudar un terapeuta del habla y el lenguaje.  Explore más sobre los cambios en el habla y la deglución en el Parkinson. Puntos clave:  La detección temprana es fundamental para reconocer los cambios al tragar y recibir el tratamiento y el apoyo adecuados.  Los cambios al tragar pueden ser difíciles de detectar. Conocer las señales comunes puede ayudar a las personas con la EP y a sus aliados en la atención a notar un cambio y buscar apoyo.  Los especialistas del habla y el lenguaje con frecuencia pueden brindar atención en persona o por telesalud. Si el acceso a la atención es limitado, aprender estrategias prácticas y saber cuándo buscar apoyo profesional puede ayudar a las personas a seguir manejando los síntomas en casa. 

Transplant iPSC-derived neurons into a Parkinson's brain and 97% die before they can restore function. Of the 3% that survive, most face the same pathogenic environment that killed the original neurons. This is the compounded biology and CMC problem defining CNS cell therapy today.Bilal Fares, neuroscience entrepreneur and co-founder of AzureCell, is translating a University of Geneva discovery into a genetically engineered iPSC platform built to solve it: neurons that don't just replace what Parkinson's destroyed, but survive the fire that destroyed them.Topics discussed:Why Bilal believes cell therapy is the future of medicine for brain diseases, and the limitations of other approaches (03:06)Bilal's personal story and the events that guided his commitment to Parkinson's research and entrepreneurship (04:03)How cell therapy might move beyond simply replacing lost neurons—using engineered cells to produce therapeutics directly in the brain (09:05)The neuroprotective technology AzureCell is developing, designed to shield transplanted neurons from Parkinson's disease mechanisms (11:31)The platform approach: combining stem cell technologies, genetic engineering, and allogeneic off-the-shelf cell banks (12:38)Why the blood-brain barrier makes cell therapy a necessary approach for certain conditions (13:26)The current status of Azure's preclinical and manufacturing development, and their plans for clinical translation (14:31)Why previous therapies for Parkinson's have fallen short, and how cell therapy might sidestep these limitations (15:57)The potential and challenges of using cell therapy for other brain diseases like Alzheimer's (18:26)Smart insight: The next generation of CNS cell therapy isn't only about neuron replacement. Bilal's thesis reframes transplanted cells as engineered biological factories inside the brain: producing neuroprotective proteins, modulating disease mechanisms in real time, and eventually enabling preventative treatment as manufacturing costs fall and safety matures.If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities.Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung WooEpisodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta LeeEpisodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale BernatchezEpisodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeConnect with Bilal Fares:LinkedIn: www.linkedin.com/in/b-fares AzureCell website: www.azurecell.co Email: info@azurecell.coSupport the show

Like an idiot, I decided to work on my backyard firepit yesterday in the extreme heat. We got six of the nine circles done before calling it quits after about two hours. It was absolutely brutal…and I will never make that mistake again. Needless to say, I'm dragging ass today. Thankfully, we had a MAJOR concert announcement this morning, which helped perk me up a bit. In case you missed it, Godsmack & Dorothy are coming to the La Crosse Center on Friday, October 16th!!! Tickets go on-sale this Friday at 10am. In the news this morning, a recall on Bacon, the CEO of Cracker Barrel is stepping down after the company's disastrous attempt at rebranding, Bryan Kohberger is attempting to change his plea, Carly Simon announces that she's got Parkinson's disease In sports, the Brewers started their west coast road trip with a loss to the Giants last night, Eric Bieniemy's wife was shot by the couple's son, Jamal Adams is signing with the Vikings, Michael Lombardi is on paid administration leave from UNC, Conor McGregor is looking to fight Max Holloway again in 2027, and FIFA President Gianni Infantino has been accused of corruption. Talked about what's on TV & streaming today/tonight and let you know what's new on New Release Tuesday. Plus, as the 25th Anniversary of 9/11 gets nearer, John Stewart & Pete Davidson announce a new comedy special to raise money for 9/11 charities. Great story from New Jersey about a cop who helped deliver a baby in a parking lot, and a dog that's been missing for five years gets reunited with it's owner. Apparently, some people are eating more iceberg lettuce & trying to get the explosive diarrhea so they'll lose weight. Elsewhere in sports, Ryan Lasko is starting to get feeling in his legs, a squirrel gets on the field and the grounds crew has a hell of a time trying to corral it, and a soccer team wins a title after 75 years of trying! In a new round of "Who'd You Rather"...$50k in cash immediately, or a coin-flip for a shot at $1 million? Grant Bilse of the Wisco Sports Show joined me just after 8am to talk about Packers training camp. And in today's edition of "Bad News with Happy Music", we had stories about a bunch of kids at a YMCA Summer camp that ate mushroom-laced edibles, a #FloridaMan who was depositing his co-workers' paychecks into his account, a woman in Iowa who got busted for DUI on a lawnmower, and a cop in Nashville who was banging another cop in a school.See omnystudio.com/listener for privacy information.

Meghan Markle lives in a false reality, Seattle shooting, TikTok murder, D4Dv trial, Bert Kreischer can't wait to drink, Nolan Wells enhanced audio, and a new Detroit podcast is on its way. Sad News: A family of 8 is dead in Grand Haven, Michigan. There was a shootout at the Bite of Seattle food festival. In Germany, some closeted ISIS turd attacked a Pride parade. A TikTok influencer was murdered by her estranged husband after calling him out for being a pedo. Bryan Kohberger claims he is innocent a little bit too late. Miley Cyrus sounds like a seal. Not everybody is thrilled with the new gig Lindsey Graham's sister landed. A 'Trust Retreat' at Netflix led to the firing of an honest employee. Be careful jumping off cliffs. Markleverse: King Charles has invited not-a-Prince Harry to Buckingham Palace. Meghan Markle embarrassed herself on MasterChef Australia. Meghan has an affinity for hot sauce. She posted an obnoxious amount of family pictures on social media. Prince Harry is bald. As Ever seems to have given up after a total failure. Poor Thomas Markle remains devastated in exile. D4vd might be up for the death penalty. His defense team thinks his text messages will clear him under self-defense. His Apple Music profile was apparently hacked. Charles Manson's granddaughter is the true victim. What is Jeff Stone up to these days? We investigate. People want Nolan Wells' white friends to have murdered him SO BAD. TMZ breaks down shocking new audio that means absolutely nothing.  The WNBA is filled with controversies at the moment. Caitlin Clark remains hated among her contemporaries. The league is kinda one giant orgy. KTV is all in on WNBA dating scene. Angel Reese remains the true victim in all this. Fritz Peterson and Mike Kekich were double Eskimo brothers. Spike is back! Looks like he's teaming up with Hank Winchester for a podcast. Anthony Cumia and Jim Norton are teaming up once again. Gregg 'Opie' Hughes, however, is broadcasting to hundreds. A Toxic Love Story on Netflix has quite the twist. Watch it. Drew still wants somebody... anybody... to watch the eBay doc. Armie Hammer's comeback has hit a roadblock. Kim Mathers is an absolute mess. New York City Mayor Zohran Mamdani doxxes wealthy New Yorkers. Some rich folks are leaving the Big Apple. Bert Kreischer can't wait to drink himself stupid again. He and Nick Swardson talked sobriety. You can get wasted with Bert on a cruise. Tony Romo was busted for drinking and driving. Faith No More is reuniting. Carly Simon has Parkinson's Disease. Jeff the Drunk famously did a duet with her. Karl from WATP will join us tomorrow. Merch, yo. Check it. If you'd like to help support the show… consider subscribing to our YouTube Channel, Facebook, Instagram and Twitter (Drew Lane, Marc Fellhauer, Trudi Daniels, Jim Bentley, BranDon, and Roberto).

From 07/27 Hour 4: The Sports Junkies are distraught to discover that legendary singer Carly Simon is battling Parkinson's disease.

Dr. Jeff Gross, a board-certified neurosurgeon and founder of Recelebrate, joins the show to demystify peptides and regenerative medicine. He explains how frustration with the traditional healthcare system pushed him from surgery toward cellular-level healing, and breaks down what peptides actually are, why "FDA approved" is widely misunderstood, and how stem cells and exosomes work in the body. The conversation covers real-world applications — from joint and cartilage regeneration to Parkinson's symptom relief and mitochondrial repair with peptides like SS-31 and MOTS-C. Dr. Gross also tackles misconceptions around legality, telehealth treatment options, and how to vet a regenerative medicine clinic. It's a wide-ranging, myth-busting conversation for anyone curious about the future of longevity and healing. Chapters: 0:00 – Introduction & sponsor message 2:37 – Meet Dr. Jeff Gross 4:18 – From surgery to regenerative medicine 12:43 – What exactly is a peptide? 22:22 – Types of stem cells and what's legal in the U.S. 25:56 – Stem cells and Parkinson's treatment 28:22 – Cartilage regeneration and joint pain 31:14 – Finding a trustworthy regenerative medicine clinic 35:23 – Mitochondrial peptides (SS-31, MOTS-C) 41:15 – Where to find Recelebrate Show Sponsor: Jason Gagne's Good2GoBody 90-day beginner fitness program - ⁠https://good2go.podia.com/?coupon=LIONSJOHN⁠ Links: Learn more: https://recellebrate.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

One of our favorite guests is back! Arkansas Senior Associate AD Kyle Parkinson joins us to talk through the offseason, and share why he's excited about this football team heading into the fall.

breaking headlines to baseball and laughs. Kimmer reacts to disturbing reports of Iranian threats against the Trump family, discusses gas prices and the economy, and shares news of Carly Simon's Parkinson's diagnosis. Pete Davis breaks down the Braves' extra-inning win over Baltimore, Andrew Jones' Hall of Fame induction, Falcons and NFL headlines, plus the latest sports oddities. The guysalso celebrate a heartwarming lost dog reunion, Pete's backyard bird adventure, and more.See omnystudio.com/listener for privacy information.

Kimmer and the crew cover a jam-packed Monday with the latest on Elon Musk's robot predictions, a bizarre Bigfoot sighting in Rhode Island, alleged revelations from Anthony Fauci's diary, Carly Simon's Parkinson's diagnosis, and a lively round of Holy Crap It's Sports. Plus, the Braves take another series, Andrew Jones enters the Baseball Hall of Fame, NFL training camp headlines, stories from around the world, Pete's backyard wildlife adventure, Flounder's Funny, andSee omnystudio.com/listener for privacy information.

Pete shares his Chattanooga adventure, Flounder talks weekend fun, and Kimmer breaks down a wild motorcycle encounter. Plus, baby birds leaving the nest, a Braves thriller, Carly Simon’s Parkinson’s announcement, a missing dog reunion, a Georgia shark attack, Bigfoot in Rhode Island, Trump’s Michigan visit, Fauci controversy, and plenty more.See omnystudio.com/listener for privacy information.

HOUR 3 (07/27) – Gary and Shannon cover the day's biggest stories in #WhatsHappening, including the latest on the deadly Seattle food festival shooting, Bryan Kohberger's attempt to undo his plea agreement, another sweltering week of summer heat, Jay-Z adding a 2nd SoFi show due to demand for his 30th anniversary tour, and Carly Simon revealing her Parkinson's diagnosis.In #SwampWatch, they discuss the latest U.S.-Iran developments, a temporary ceasefire, and fresh "proof of life" from Mitch McConnell.The hour wraps with a conversation about why so many Gen Z adults blame helicopter parenting for their lack of independence before diving into the booming rental economy, where luxury fashion is becoming something you access instead of own.See omnystudio.com/listener for privacy information.

Aaron Leonard and Donald Parkinson sit down for a conversation on Leonard's recent book 'Menace of Our Time: The Long War Against American Communism'. Relating this history to current events, Leonard and Parkinson discuss the various ways that the U.S. government, and in particular the FBI, subverted civil liberties and indulged in state repression according to the ebbs and flows of geopolitics while never abandoning its agenda of surveillance and subversion of the Communist Movement. From the early days of Criminal Syndicalism laws and the Palmer Raids to the rise of the New Left and the marginalization of the Party, the long arc of a campaign of espionage that utilized legal and extra-legal tactics provides an important window into the nature of state repression against left-wing dissidents in a country that is supposedly a bastion of political liberty.

Dr. Jeff Gross, a board-certified neurosurgeon and founder of Recelebrate, joins the show to demystify peptides and regenerative medicine. He explains how frustration with the traditional healthcare system pushed him from surgery toward cellular-level healing, and breaks down what peptides actually are, why "FDA approved" is widely misunderstood, and how stem cells and exosomes work in the body. The conversation covers real-world applications — from joint and cartilage regeneration to Parkinson's symptom relief and mitochondrial repair with peptides like SS-31 and MOTS-C. Dr. Gross also tackles misconceptions around legality, telehealth treatment options, and how to vet a regenerative medicine clinic. It's a wide-ranging, myth-busting conversation for anyone curious about the future of longevity and healing. Chapters: 0:00 – Introduction & sponsor message 2:37 – Meet Dr. Jeff Gross 4:18 – From surgery to regenerative medicine 12:43 – What exactly is a peptide? 22:22 – Types of stem cells and what's legal in the U.S. 25:56 – Stem cells and Parkinson's treatment 28:22 – Cartilage regeneration and joint pain 31:14 – Finding a trustworthy regenerative medicine clinic 35:23 – Mitochondrial peptides (SS-31, MOTS-C) 41:15 – Where to find Recelebrate Show Sponsor: Jason Gagne's Good2GoBody 90-day beginner fitness program - ⁠https://good2go.podia.com/?coupon=LIONSJOHN⁠ Links: Learn more: https://recellebrate.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Today we're talking about BeechBand, a wearable wellness device designed to support people living with neurological conditions, including Parkinson's disease. If you've spent any time in the Parkinson's community lately, you've probably heard the name. Carl Beech, the co-inventor and founder, seems to be everywhere sharing the story behind this innovative wearable. Friends of mine who have purchased a BeechBand rave about the results. Carl regularly appears in my Instagram feed, and when I attended the World Parkinson's Congress (WPC) in May, his booth was consistently packed with people eager to learn more. It's clear that the word is getting out, and BeechBand appears to be gaining real momentum. I have to admit—I became a believer myself. In this episode, Carl shares the origins of BeechBand, the personal story that inspired its creation, and how the device is designed to help people with Parkinson's. Listen in to discover what makes this wearable so intriguing. You just might become a believer, too. https://www.beechband.com/pages/about Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches